Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Clin Pharmacol ; 51(2): 212-7, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20400649

RESUMO

The aim of this study is to determine the concentrations of lidocaine and its metabolite, monoethylglycine xylidide (MEGX), and of the enantiomers of bupivacaine in maternal and fetal compartments. Ten healthy pregnant women were submitted to epidural anesthesia. Drug concentrations were determined in the maternal vein, fetal umbilical artery and vein, and the placental intervillous space. The highest concentrations of the bupivacaine enantiomers lidocaine and of lidocaine and of its MEGX metabolite were detected in maternal plasma and in the placental intervillous space. The placental transfer was 33% for the (+)-(R)-bupivacaine enantiomer and 31% for the (-)-(S)-bupivacaine enantiomer. For lidocaine and its MEGX metabolite, respective placental transfers were 60% and 43%. Lidocaine concentration in the fetal umbilical vein was 1.46 times higher than in the fetal umbilical artery. The highest concentrations of lidocaine and its metabolite and of the enantiomers of bupivacaine were detected in the placental intervillous space. The higher lidocaine concentrations in the fetal umbilical vein than in the fetal umbilical artery suggest that there was tissue uptake of the drug or drug metabolization by the fetus.


Assuntos
Anestésicos Locais/farmacocinética , Bupivacaína/farmacocinética , Lidocaína/análogos & derivados , Lidocaína/farmacocinética , Adulto , Anestesia Epidural/métodos , Anestesia Obstétrica/métodos , Anestésicos Locais/química , Bupivacaína/química , Vilosidades Coriônicas/metabolismo , Feminino , Humanos , Placenta/metabolismo , Gravidez , Estereoisomerismo , Distribuição Tecidual , Artérias Umbilicais/metabolismo , Veias Umbilicais/metabolismo , Adulto Jovem
2.
Eur J Clin Pharmacol ; 65(8): 803-8, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19330322

RESUMO

BACKGROUND: Fentanyl is used in obstetrical practice to promote analgesia and anesthesia during labor and in cesarean delivery, with rapid and short-term effects. OBJECTIVE: To determine fentanyl concentrations in maternal plasma, in the placental intervillous space, and in the umbilical artery and vein in term pregnant women. PATIENTS AND METHODS: Ten healthy pregnant women underwent epidural anesthesia with fentanyl plus bupivacaine and lidocaine, and fentanyl concentrations were determined in the various maternal and fetal compartments, including the placental intervillous space, which has not been previously studied in the literature. RESULTS: The ratios of fentanyl concentrations in the various maternal and fetal compartments revealed an 86% rate of placental fentanyl transfer. The highest fentanyl concentrations were detected in the placental intervillous space, being 2.19 times higher than in maternal plasma, 2.8 times higher than in the umbilical vein and 3.6 times higher than in the umbilical artery, with no significant differences between the umbilical vein and artery, demonstrating that there was no drug uptake by fetal tissues nor metabolism of the drug by the fetus despite the high rates of placental transfer. CONCLUSION: The present study demonstrated that the placental intervillous space acted as a site of fentanyl deposit, a fact that may be explained by two hypotheses: (1) the blood collected from the placental intervillous space is arterial and, according to some investigators, the arterial plasma concentrations of the drugs administered to patients undergoing epidural anesthesia are higher than the venous concentrations, and (2) a possible role of P-glycoprotein (P-gp).


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Analgésicos Opioides/farmacocinética , Anestésicos Intravenosos/farmacocinética , Fentanila/farmacocinética , Feto/metabolismo , Placenta/metabolismo , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/efeitos dos fármacos , Adulto , Analgesia Obstétrica/métodos , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/sangue , Anestesia Obstétrica/métodos , Anestésicos Intravenosos/administração & dosagem , Anestésicos Intravenosos/sangue , Vilosidades Coriônicas/metabolismo , Feminino , Fentanila/administração & dosagem , Fentanila/sangue , Humanos , Gravidez
3.
Chirality ; 21(8): 738-44, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19006203

RESUMO

Labetalol is clinically available as a mixture of two racemates (four stereoisomers). The stereoisomer (R,R) has as main activity the beta1-antagonism and the stereoisomer (S,R) is highly selective for the alpha1 adrenoceptor and is responsible for most of the alpha-blocker activity. In the present investigation, a method for the analysis of labetalol stereoisomers in human plasma was developed and applied to pharmacokinetic studies. Plasma samples (0.5 ml) were extracted with methyl tert-butyl ether at pH 9.5. The four labetalol stereoisomers were analyzed by LC-MS/MS on a Chirobiotic V column using a mobile phase consisting of methanol, acetic acid, and diethylamine, with a recovery of more than 90% for all four. The quantitation limit was 0.5 ng/ml and linearity was observed at 250 ng/ml plasma for each stereoisomer. Studies of precision and accuracy presented coefficients of variation and percentage inaccuracy of less than 15%, indicating that the method is precise and accurate. The method was applied to the study of the kinetic disposition of labetalol over a period of 12 h after oral administration of a single 100 mg dose to a hypertensive pregnant woman. The clinical study revealed stereoselectivity in the pharmacokinetics of labetalol, with a lower plasma proportion for the active stereoisomers (R,R)-labetalol and (S,R)-labetalol. The stereoselectivity observed after oral administration is due to the hepatic metabolism and the first pass effect, with an AUC(R,R)/AUC(S,S) ratio of 0.5.


Assuntos
Labetalol/química , Farmacocinética , Anti-Hipertensivos/sangue , Anti-Hipertensivos/química , Cromatografia Líquida de Alta Pressão , Feminino , Humanos , Labetalol/sangue , Estrutura Molecular , Gravidez , Estereoisomerismo , Espectrometria de Massas em Tandem
4.
Eur J Clin Pharmacol ; 64(12): 1189-96, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18679666

RESUMO

BACKGROUND: Peridural blockade with lidocaine, bupivacaine, and fentanyl is an anesthetic procedure extensively used in obstetrics, justifying the pharmacokinetic study of these drugs during labor. OBJECTIVE: To investigate the influence of the physiopathological changes of gestational diabetes mellitus (GDM) on the pharmacokinetics of lidocaine and its metabolite monoethylglycinexylidide (MEGX) in pregnant women subjected to peridural anesthesia. PATIENTS AND METHODS: Ten normal pregnant women (group 1) and six pregnant women with GDM (group 2) were studied, all of them at term. The patients received 200 mg 2% lidocaine hydrochloride without a vasoconstrictor by the peridural locoregional route. Maternal blood samples were collected at predetermined times for the analysis of lidocaine and MEGX by chromatography and pharmacokinetic analysis. RESULTS: The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P

Assuntos
Anestesia Epidural , Anestésicos Locais/farmacocinética , Diabetes Gestacional/metabolismo , Lidocaína/análogos & derivados , Adulto , Anestésicos Locais/administração & dosagem , Anestésicos Locais/sangue , Anestésicos Locais/uso terapêutico , Área Sob a Curva , Cromatografia Líquida de Alta Pressão , Citocromo P-450 CYP1A2/metabolismo , Citocromo P-450 CYP3A/metabolismo , Diabetes Gestacional/sangue , Diabetes Gestacional/enzimologia , Feminino , Humanos , Lidocaína/administração & dosagem , Lidocaína/sangue , Lidocaína/farmacocinética , Lidocaína/uso terapêutico , Taxa de Depuração Metabólica , Gravidez , Fatores de Tempo , Adulto Jovem
5.
J Chromatogr B Analyt Technol Biomed Life Sci ; 852(1-2): 640-5, 2007 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-17307403

RESUMO

A method for the determination of pindolol enantiomers in amniotic fluid and breast milk was developed, validated, and applied to the investigation of six pregnant women treated with rac-pindolol (10 mg/12 h). Biological samples were extracted with tert-methyl-butyl ether, and the pindolol enantiomers were resolved on a Chiralpak AD column. Amniotic fluid/plasma and milk/plasma concentrations ratios ranged from 0.4 to 4.5 and from 0.6 to 3.7, respectively, for (+)-R-pindolol and from 0.5 to 3.5 and from 1.1 to 2.8, respectively, for (-)-S-pindolol. Preliminary data suggest that amniotic fluid and breast milk are routes of fetal exposure to pindolol enantiomers.


Assuntos
Líquido Amniótico/química , Anti-Hipertensivos/análise , Lactação , Leite Humano/química , Pindolol/análise , Adulto , Anti-Hipertensivos/farmacocinética , Feminino , Humanos , Pindolol/farmacocinética , Gravidez , Reprodutibilidade dos Testes , Espectrometria de Fluorescência , Estereoisomerismo
6.
J Pharm Biomed Anal ; 40(2): 389-96, 2006 Feb 13.
Artigo em Inglês | MEDLINE | ID: mdl-16243469

RESUMO

A LC/MS/MS method for the quantitative determination of lorazepam in human plasma and urine samples was developed and validated. The enantioselective assay allowed to separate the enantiomers and to verify the stereochemical instability of lorazepam. The linearity assessed for lorazepam unchanged was 0.2-20 ng of each enantiomer/ml plasma and 0.2-15 ng of each enantiomer/ml urine. The linearity assessed for total lorazepam (after enzymatic hydrolysis) was 1-30 ng of each enantiomer/ml plasma and 10-150 ng of each enantiomer/ml urine. The coefficients of variation obtained for the intra- and interassay precision were less than 15%. The method was applied to the investigation of the kinetic disposition and metabolism of racemic lorazepam administered as a single oral dose of 2 mg to a parturient. The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg). However, the determined confidence limits make the method suitable for application to clinical pharmacokinetic studies, even if the quantification of both the enantiomers is required.


Assuntos
Ansiolíticos/farmacocinética , Cromatografia Líquida/métodos , Lorazepam/análogos & derivados , Acetonitrilas , Ansiolíticos/sangue , Ansiolíticos/urina , Estabilidade de Medicamentos , Feminino , Humanos , Lorazepam/sangue , Lorazepam/farmacocinética , Lorazepam/urina , Parto/metabolismo , Gravidez , Reprodutibilidade dos Testes , Espectrometria de Massas por Ionização por Electrospray
7.
J Pharm Biomed Anal ; 40(2): 397-403, 2006 Feb 13.
Artigo em Inglês | MEDLINE | ID: mdl-16143486

RESUMO

The present study investigates the kinetic disposition with focus on the racemization, glucuronidation capacity and the transplacental transfer of lorazepam in term parturients during labor. The study was conducted on 10 healthy parturients aged 18-37 years with a gestational age of 36-40.1 weeks, treated with a single oral dose of 2 mg racemic lorazepam 2-9 h before delivery. Maternal venous blood and urine samples were obtained over a 0-48 h interval and the umbilical cord sample was obtained immediately after clamping. Lorazepam enantiomers were determined in plasma and urine samples by LC-MS/MS using a Chiralcel OD-R column. In vitro racemization of lorazepam required the calculation of the pharmacokinetic parameters as isomeric mixtures. The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)). Placental transfer of lorazepam evaluated as the ratio of vein umbilical/maternal vein plasma concentrations, obtained as an isomeric mixture, was 0.73 (0.52-0.94). Pregnancy changes the pharmacokinetics of lorazepam, with an increase in the apparent distribution volume, an increase in apparent oral clearance, and a reduction of elimination half-life. The increase in oral clearance may indicate an increase in glucuronidation capacity, with a possible reduction in the plasma concentrations of drugs depending on glucuronidation capacity as the major metabolic pathway.


Assuntos
Ansiolíticos/farmacocinética , Lorazepam/análogos & derivados , Parto/metabolismo , Adolescente , Adulto , Ansiolíticos/sangue , Cromatografia Líquida/métodos , Feminino , Sangue Fetal/metabolismo , Idade Gestacional , Humanos , Lorazepam/sangue , Lorazepam/farmacocinética , Troca Materno-Fetal , Gravidez , Espectrometria de Massas por Ionização por Electrospray
8.
Eur J Clin Pharmacol ; 61(7): 517-22, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16021436

RESUMO

BACKGROUND: Fentanyl is an opioid drug widely used as a co-adjuvant in abdominal delivery, a fact that justifies its pharmacokinetic study under these conditions. OBJECTIVE: Our objective was to investigate the pharmacokinetics and placental transfer of fentanyl in parturients whose pregnancies were resolved by cesarian section with epidural anesthesia. PATIENTS AND METHODS: Ten clinically normal parturients who delivered at term received 5 ml of 2% lidocaine hydrochloride without a vasoconstrictor for skin and subcutaneous blockade, followed by epidural injection of 2 ml fentanyl citrate (0.05 mg/ml), 15 ml 0.5% bupivacaine hydrochloride with 1:200,000 epinephrine, and 10 ml 2% lidocaine hydrochloride without a vasoconstrictor. Maternal blood samples were collected at various times after injection (1--840 min), and the fentanyl plasma concentrations were determined by gas chromatography-mass spectrometry. Pharmacokinetic analysis was performed using the bi- or tri-compartmental model. The fetal/maternal ratio of the plasma fentanyl was determined at birth. RESULTS: The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg. The latency between drug administration and birth was 28.5 min, with a maternal and fetal plasma concentration of 0.310 and 0.245 ng/ml, respectively, at a median fetal/maternal ratio of 0.892. CONCLUSION: The study demonstrated a rapid passage of fentanyl from the epidural space to maternal blood and a significant transplacental transfer of maternal fentanyl of about 90%, which should serve as an alert to obstetricians.


Assuntos
Analgésicos Opioides/farmacocinética , Fentanila/farmacocinética , Troca Materno-Fetal , Placenta/metabolismo , Analgesia Epidural , Analgésicos Opioides/administração & dosagem , Feminino , Fentanila/administração & dosagem , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Gravidez , Sensibilidade e Especificidade , Distribuição Tecidual
9.
Eur J Clin Pharmacol ; 60(8): 569-74, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15365654

RESUMO

BACKGROUND: Obstetrical analgesia continues to be challenging to science in the search for safe and effective methods that will permit the use of these procedures allied to improved obstetrical and perinatal results. OBJECTIVE: The objective of the present study was to investigate the pharmacokinetics and the placental transfer of lidocaine and its metabolite in parturients whose pregnancies were resolved by the vaginal route under perineal analgesia. PATIENTS AND METHODS: The study was conducted on 23 pregnant women who received perineal analgesia with 20 ml 2% lidocaine (400 mg) during the expulsive period of labor. Maternal venous blood samples were obtained from 0 min to 360 min after drug administration, and umbilical venous blood was obtained at delivery. Lidocaine and monoethylglycinexylidide (MEGX) were determined using high-performance liquid chromatography. The fetal/maternal ratios of the drugs were determined on the basis of maternal and fetal concentrations at delivery. RESULTS: Maximum lidocaine concentrations at the median times of 15 min were 3.22 microg/ml. The pharmacokinetic parameters were: half-life t1/2alpha 24.0 min, area under the curve (AUC)0-infinity 460.2 microg/min per ml, t1/2beta 180.0 min, clearance 12.2 ml/min per kg and volume distribution 3.1 l/kg. The fetal/maternal ratio for lidocaine at delivery was 0.46, with the latency time between drug administration and delivery being 11.0 min. Maximum MEGX concentrations at the median time of 90 min were 229.0 ng/ml. The t1/2 for MEGX was 240 min, and AUC0-infinity was 82.4 microg min/ml. CONCLUSION: Lidocaine administered by the perineal route presented a tmax of 15 min, significantly lower than when the drug was administered peridurally, revealing that the time between administration and the occurrence of the analgesic effect was shorter. The study demonstrated placental transfer of lidocaine at ratios of about 50% for lidocaine at the time of delivery. The MEGX placental transfer demonstrated fetal concentration higher than the maternal at the time of delivery.


Assuntos
Analgesia Obstétrica , Anestésicos Locais/farmacocinética , Lidocaína/farmacocinética , Placenta/metabolismo , Adulto , Anestésicos Locais/administração & dosagem , Área Sob a Curva , Feminino , Humanos , Lidocaína/administração & dosagem , Períneo , Gravidez
10.
Chirality ; 14(8): 683-7, 2002 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12125040

RESUMO

Nine patients taking oral doses of 10 mg/12 h rac-pindolol as part of their treatment for hypertension in pregnancy were recruited for the study. Maternal and fetal gestational age ranged from 20-38 years and 28-41 weeks, respectively. Blood was collected from the umbilical cord vein and from the mother from zero to 12 h after drug administration. Urine was collected for 12 h after rac-pindolol administration at the following intervals: 0-3, 3-6, 6-9, and 9-12 h. Plasma and urine concentrations of the pindolol enantiomers were determined by HPLC using a Chiralpak AD chiral column and fluorescence detection. The data were fitted to a one-compartment model and differences between (+)-R and (-)-S enantiomers were compared by the paired t-test (P < 0.05). Mean results are reported. The disposition of pindolol in maternal plasma was stereoselective, with higher AUC(SS)0-12 (84.34 vs. 95.69 ng.h/ml) and Cl(R) values (9.16 vs. 10.85 L/h) and lower Vd/f (251.38 vs. 225.17 L) and Cl/f (62.48 vs. 55.74 L/h) for the (+)-R pindolol. The transplacental distribution of pindolol was not stereoselective. Cord, plasma, and presumably fetal, concentrations of the pindolol enantiomers were 56% of the maternal plasma concentrations up to 6 h after the last dose.


Assuntos
Antagonistas Adrenérgicos beta/farmacocinética , Anti-Hipertensivos/farmacocinética , Hipertensão/tratamento farmacológico , Pindolol/farmacocinética , Placenta/metabolismo , Complicações Cardiovasculares na Gravidez/tratamento farmacológico , Adulto , Feminino , Humanos , Hipertensão/metabolismo , Gravidez , Complicações Cardiovasculares na Gravidez/metabolismo , Estereoisomerismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA